The high prevalence of obesity in Europe is similar to that in other industrialized areas. Obesity and its related diseases, such as hypertension, hyperlipidemia, diabetes, and hyperuricemia, have become a major problem, particularly in terms of cost. Prospective studies in Scandinavia strongly suggest obesity and its related diseases lower life expectancy. Divergent results from the Seven Countries Study are critically discussed.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.7326/0003-4819-103-6-1037 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Treatment Utilisation and Satisfaction With Management in Individuals With Osteoarthritis and Metabolic Multimorbidity: A Cross-Sectional Multi-Country Study.
Musculoskeletal Care
March 2025
Department of Clinical Sciences, Clinical Epidemiology Unit, Orthopaedics, Lund University, Lund, Sweden.
Purpose: To compare treatment utilisation for osteoarthritis (OA) and satisfaction with OA management between individuals with and without comorbid metabolic conditions (e.g., diabetes, obesity, dyslipidaemia, hypertension).
View Article and Find Full Text PDFEffect of dietary phenolic compounds intake on mortality in the "Seguimiento Universidad De Navarra" (SUN) Mediterranean cohort.
Eur J Nutr
January 2025
Department of Preventive Medicine and Public Health, University of Navarra, Instituto de Investigación Sanitaria de Navarra (IdiSNA), Pamplona, Spain.
Plant-based dietary patterns have been demonstrated to reduce the risk of non-communicable disease (NCD), including cardiovascular disease (CVD), type 2 diabetes, cancer, and all-cause mortality. Phenolic compounds (PC), abundant in plant-based foods, have been considered as instrumental in this attenuation of NCD risk. We evaluated the association between dietary intake of PC and the risk of all-cause mortality in a relatively young Mediterranean cohort of 18,173 Spanish participants in the "Seguimiento Universidad de Navarra" (SUN) project, after a median follow-up of 12.
View Article and Find Full Text PDFInvolving national stakeholders in a systems approach to map drivers of childhood obesity and actions to prevent childhood obesity in Denmark: the Generation Healthy Kids Study.
Health Res Policy Syst
January 2025
Center for Clinical Research and Prevention, Health Promotion and Prevention, Frederiksberg Hospital, Frederiksberg, Denmark.
Background: Childhood obesity is a preventable global public health challenge, increasingly recognized as a complex problem, stemming from complex drivers. Obesity is characterized by multiple interdependencies and diverse influences at different societal levels. Tackling childhood obesity calls for a holistic approach that engages with complexity and recognizes that there is no single "magic bullet" intervention to prevent obesity.
View Article and Find Full Text PDFGlobal, regional, and national burden of low back pain for adults aged 55 and older 1990-2021: an analysis for the global burden of disease study 2021.
BMC Musculoskelet Disord
January 2025
Department of Internal medicine, Jieyang People's Hospital, Tianfu Road 107, Rongcheng district, Jieyang, 522000, Guangdong, China.
Background: Low back pain (LBP) is a widespread condition that increasingly affects the older adults, highlighting the need for a detailed examination of its global impact. Our research aimed to evaluate the LBP's burden and trends in individuals over 55 years of age across 204 countries and territories from 1990 to 2021.
Methods: We analyzed the data from the Global Burden of Disease 2021, focusing on LBP prevalence, incidence, and years lived with disability (YLDs), along with associated risk factors.
Semaglutide in obesity-related heart failure with preserved ejection fraction and type 2 diabetes across baseline HbA levels (STEP-HFpEF DM): a prespecified analysis of heart failure and metabolic outcomes from a randomised, placebo-controlled trial.
Lancet Diabetes Endocrinol
January 2025
Department of Cardiovascular Disease, Saint Luke's Mid America Heart Institute, University of Missouri-Kansas City School of Medicine, Kansas City, MO, USA. Electronic address:
Background: About half of patients with heart failure with mildly reduced or preserved ejection fraction (HFpEF) have type 2 diabetes. In the STEP-HFpEF DM trial of adults with obesity-related HFpEF and type 2 diabetes, subcutaneous once weekly semaglutide 2·4 mg conferred improvements in heart failure-related symptoms and physical limitations, bodyweight, and other heart failure outcomes. We aimed to determine whether these effects of semaglutide differ according to baseline HbA.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!